Cardiomyopathy News and Research

RSS

Cardiomyopathy is a group of diseases with primary, usually diffuse, involvement of the myocardium. The myocardial disease is not secondary to ischaemic, valvular, congenital or pericardial disease.

Pfizer enters agreement to acquire FoldRx Pharmaceuticals

Pfizer Inc. and FoldRx Pharmaceuticals, Inc., a privately held drug discovery and clinical development company, today announced that they have entered into an agreement under which Pfizer will acquire FoldRx.

2 Sep 2010

ECG-based screening for young footballers at risk of heart disease needs to be reviewed: Study

The screening process for young footballers at risk of heart disease needs to be re-evaluated. That is the conclusion of a recent study, which has shown that the common criteria used for assessment does not take into account the type and intensity of the exercise performed. The single most common cause of sudden death in competitive footballers is hypertrophic cardiomyopathy - a disease that thickens the heart muscle without any obvious cause.

31 Aug 2010

International Symposium to explore Hybrid approach for congenital heart disease

Interventional cardiologists and cardiothoracic surgeons throughout the United States and the world, who treat patients with congenital heart disease, will gather at the Hilton Columbus at Easton Town Center August 31-September 2, 2010 for the International Symposium on the Hybrid Approach to Congenital Heart Disease (ISHAC).

31 Aug 2010

Study finds black females exhibit greater magnitude of LVH than their white counterparts

A study conducted in the UK has established the extent of cardiac adaptation amongst female athletes competing in a number of sports.

31 Aug 2010

Cardiac adaptations in elite triathletes not associated with sudden cardiac death: Study

A study of triathletes published in the online edition and October issue of Radiology reveals that the heart adapts to triathlon training by working more efficiently.

31 Aug 2010

Selective lowering of heart rate reduces risk of death and hospitalization: Study

The results of a major international study presented at the European Society of Cardiology Congress in Stockholm and published simultaneously in The Lancet show, for the first time, that selectively lowering heart rate with a novel medication, ivabradine, significantly reduces risk of death and hospitalization for patients with heart failure. This also resolves a longstanding debate about whether lowering heart rate itself can actually lower the risk of heart disease progression.

30 Aug 2010

UNC Hospitals receives NCDR ACTION Registry-GWTG Silver Performance Achievement Award

UNC Hospitals has received the American College of Cardiology Foundation's NCDR ACTION Registry-GWTG Silver Performance Achievement Award for 2010 - one of only 26 hospitals nationwide to do so.

26 Aug 2010

HCM patients undergoing transplant can expect reasonable long-term survival rates: Research

Transplant surgery to correct the most common type of genetic heart disease yields similar short-term and potentially greater long-term survival rates as transplant surgery for other heart diseases, according to research reported in Circulation: Heart Failure, an American Heart Association journal.

25 Aug 2010

St. Vincent's Hospital performs Australia's first implant of SynCardia temporary Total Artificial Heart

On Aug. 5, St. Vincent's Hospital in Sydney performed Australia's first implant of the SynCardia temporary Total Artificial Heart. The patient, a 50-year-old male suffering from total heart failure, is the first recipient of the Total Artificial Heart in the Southern Hemisphere. The surgery was performed by heart surgeons Drs. Phillip Spratt and Paul Jansz.

20 Aug 2010

Results from TITAN trial of CARILLON Mitral Contour System to be presented at ESC 2010 Congress

Cardiac Dimensions, an early stage company focused on the development of minimally invasive devices for the treatment of mitral valve disease and congestive heart failure, announced today that the 12-month follow-up results from the TITAN trial of the Company's CARILLON Mitral Contour System will be presented at the European Society of Cardiology 2010 Congress on August 29, 2010 in Stockholm.

18 Aug 2010

Aastrom Bioscience fourth quarter net loss decreases to $0.18 per share

Aastrom Biosciences, Inc., the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today reported operating results for the fourth quarter and fiscal year ended June 30, 2010.

18 Aug 2010

Australia’s first artificial heart in place

Angelo Tigano, 50 was given only two weeks to live at the start of this month. But last week surgeons at St Vincent's Hospital, Sydney gave him the country's first artificial heart after a five-hour operation to keep him alive.

16 Aug 2010

New implantable device to prevent sudden cardiac arrest

Northwestern Memorial Hospital heart rhythm specialists recently gave a 34-year-old man a makeshift paramedic—who's always on duty—inside of his chest by implanting a device that did not require X-ray assistance and the usual snaking of wires leading to the heart. In fact, the innovative device rests just beneath the surface of the skin and its components are positioned using the patient's own anatomical landmarks.

13 Aug 2010

TomTec releases new version of 2D Cardiac Performance Analysis package

TomTec launches the latest version of its 2D Cardiac Performance Analysis package as part of TomTec's Image-Arena™ multimodality imaging solution.

11 Aug 2010

Spinal muscular atrophy may lead to cardiac dysfunction: Study

Along with skeletal muscles, it may be important to monitor heart function in patients with spinal muscular atrophy (SMA). These are the findings from a study conducted by Nationwide Children's Hospital and published online ahead of print in Human Molecular Genetics. This is the first study to report cardiac dysfunction in mouse models of SMA.

11 Aug 2010

Clinical Data first-quarter gross revenue increases 52% to $6.2 million

Clinical Data, Inc. today announced operational and financial results for the first quarter ended June 30, 2010, noting key accomplishments including the acceptance of the Company's new drug application (NDA) for vilazodone by the U.S. Food and Drug Administration (FDA) and the successful completion of a public offering .

9 Aug 2010

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.

5 Aug 2010

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck announced a non-exclusive license agreement with Laboratory Corporation of America Holdings for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus infection to peginterferon alpha-based therapy.

28 Jul 2010

Study tests new performance intervention to improve heart failure patients in outpatient setting

A study led by UCLA tested a new performance intervention to help improve adherence to national guideline-recommended therapies for heart failure patients in an outpatient setting.

27 Jul 2010

First triple-organ transplantation performed on young Brenham resident at Texas Children's Hospital

Texas Children's Hospital in Houston has performed the hospital's first triple-organ transplant on a 16-year-old Brenham resident. The patient, Taylor Sherrouse, underwent a 13-hour surgery on Tuesday, June 22 to replace her heart, lungs and liver, which had been severely damaged by cystic fibrosis. Taylor is one of only three pediatric patients in the country this decade to receive heart, lungs and liver in one operation.

15 Jul 2010

Cardiomyopathy News and Research

Further Reading

Pfizer enters agreement to acquire FoldRx Pharmaceuticals

ECG-based screening for young footballers at risk of heart disease needs to be reviewed: Study

International Symposium to explore Hybrid approach for congenital heart disease

Study finds black females exhibit greater magnitude of LVH than their white counterparts

Cardiac adaptations in elite triathletes not associated with sudden cardiac death: Study

Selective lowering of heart rate reduces risk of death and hospitalization: Study

UNC Hospitals receives NCDR ACTION Registry-GWTG Silver Performance Achievement Award

HCM patients undergoing transplant can expect reasonable long-term survival rates: Research

St. Vincent's Hospital performs Australia's first implant of SynCardia temporary Total Artificial Heart

Results from TITAN trial of CARILLON Mitral Contour System to be presented at ESC 2010 Congress

Aastrom Bioscience fourth quarter net loss decreases to $0.18 per share

Australia’s first artificial heart in place

New implantable device to prevent sudden cardiac arrest

TomTec releases new version of 2D Cardiac Performance Analysis package

Spinal muscular atrophy may lead to cardiac dysfunction: Study

Clinical Data first-quarter gross revenue increases 52% to $6.2 million

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Study tests new performance intervention to improve heart failure patients in outpatient setting

First triple-organ transplantation performed on young Brenham resident at Texas Children's Hospital

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News